Seaport Startup Snags $1.9 Billion Kidney Deal With Lilly
Eli Lilly has partnered with Boston’s Ascidian to develop RNA exon‑editing therapies for inherited kidney diseases in a deal that could be worth up to $1.9 billion. The collaboration pairs Ascidian’s platform with Lilly’s Seaport genetic‑medicine hub.
Dartmouth Health Muscles Into North Country With Littleton Hospital Deal
Dartmouth Health has signed a letter of intent to bring Littleton Regional Healthcare into its network and rebranded its home‑health agency to expand rural access. Leaders say new digital tools and a capacity center aim to keep more care close to home.












